Search Results - "SYMMANS, Fraser W"

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline by Korde, Larissa A, Somerfield, Mark R, Carey, Lisa A, Crews, Jennie R, Denduluri, Neelima, Hwang, E Shelley, Khan, Seema A, Loibl, Sibylle, Morris, Elizabeth A, Perez, Alejandra, Regan, Meredith M, Spears, Patricia A, Sudheendra, Preeti K, Symmans, W Fraser, Yung, Rachel L, Harvey, Brittany E, Hershman, Dawn L

“…To develop guideline recommendations concerning optimal neoadjuvant therapy for breast cancer. ASCO convened an Expert Panel to conduct a systematic review of…”
Get full text

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study by Hurvitz, Sara A, Martin, Miguel, Jung, Kyung Hae, Huang, Chiun-Sheng, Harbeck, Nadia, Valero, Vicente, Stroyakovskiy, Daniil, Wildiers, Hans, Campone, Mario, Boileau, Jean-François, Fasching, Peter A, Afenjar, Karen, Spera, Gonzalo, Lopez-Valverde, Vanesa, Song, Chunyan, Trask, Peter, Boulet, Thomas, Sparano, Joseph A, Symmans, W Fraser, Thompson, Alastair M, Slamon, Dennis

“…The KRISTINE study compared neoadjuvant trastuzumab emtansine plus pertuzumab (T-DM1+P) with docetaxel, carboplatin, trastuzumab plus P (TCH+P) for the…”
Get full text

Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes by MASUDA, Hiroko, BAGGERLY, Keith A, FRASER SYMMANS, W, UENO, Naoto T, YING WANG, YA ZHANG, GONZALEZ-ANGULO, Ana Maria, MERIC-BERNSTAM, Funda, VALERO, Vicente, LEHMANN, Brian D, PIETENPOL, Jennifer A, HORTOBAGYI, Gabriel N

“…The clinical relevancy of the 7-subtype classification of triple-negative breast cancer (TNBC) reported by Lehmann and colleagues is unknown. We investigated…”
Get full text

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update by Allison, Kimberly H, Hammond, M Elizabeth H, Dowsett, Mitchell, McKernin, Shannon E, Carey, Lisa A, Fitzgibbons, Patrick L, Hayes, Daniel F, Lakhani, Sunil R, Chavez-MacGregor, Mariana, Perlmutter, Jane, Perou, Charles M, Regan, Meredith M, Rimm, David L, Symmans, W Fraser, Torlakovic, Emina E, Varella, Leticia, Viale, Giuseppe, Weisberg, Tracey F, McShane, Lisa M, Wolff, Antonio C

“…To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR)…”
Get full text

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial by Hurvitz, Sara A, Martin, Miguel, Symmans, W Fraser, Jung, Kyung Hae, Huang, Chiun-Sheng, Thompson, Alastair M, Harbeck, Nadia, Valero, Vicente, Stroyakovskiy, Daniil, Wildiers, Hans, Campone, Mario, Boileau, Jean-François, Beckmann, Matthias W, Afenjar, Karen, Fresco, Rodrigo, Helms, Hans-Joachim, Xu, Jin, Lin, Yvonne G, Sparano, Joseph, Slamon, Dennis

“…HER2-targeted treatments have improved outcomes in patients with HER2-positive breast cancer in the neoadjuvant, adjuvant, and metastatic settings; however,…”
Get full text

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial by Loibl, Sibylle, O'Shaughnessy, Joyce, Untch, Michael, Sikov, William M, Rugo, Hope S, McKee, Mark D, Huober, Jens, Golshan, Mehra, von Minckwitz, Gunter, Maag, David, Sullivan, Danielle, Wolmark, Norman, McIntyre, Kristi, Ponce Lorenzo, Jose J, Metzger Filho, Otto, Rastogi, Priya, Symmans, W Fraser, Liu, Xuan, Geyer, Charles E

“…Although several randomised trials in patients with triple-negative breast cancer have shown that the addition of carboplatin, with or without poly(ADP-ribose)…”
Get full text

Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial by Boughey, Judy C, Suman, Vera J, Mittendorf, Elizabeth A, Ahrendt, Gretchen M, Wilke, Lee G, Taback, Bret, Leitch, A. Marilyn, Kuerer, Henry M, Bowling, Monet, Flippo-Morton, Teresa S, Byrd, David R, Ollila, David W, Julian, Thomas B, McLaughlin, Sarah A, McCall, Linda, Symmans, W. Fraser, Le-Petross, Huong T, Haffty, Bruce G, Buchholz, Thomas A, Nelson, Heidi, Hunt, Kelly K

“…IMPORTANCE Sentinel lymph node (SLN) surgery provides reliable nodal staging information with less morbidity than axillary lymph node dissection (ALND) for…”
Get full text

Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update by Allison, Kimberly H, Hammond, M Elizabeth H, Dowsett, Mitchell, McKernin, Shannon E, Carey, Lisa A, Fitzgibbons, Patrick L, Hayes, Daniel F, Lakhani, Sunil R, Chavez-MacGregor, Mariana, Perlmutter, Jane, Perou, Charles M, Regan, Meredith M, Rimm, David L, Symmans, W Fraser, Torlakovic, Emina E, Varella, Leticia, Viale, Giuseppe, Weisberg, Tracey F, McShane, Lisa M, Wolff, Antonio C

“…To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen receptor (ER) and progesterone receptor…”
Get full text

Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy by FRASER SYMMANS, W, PEINTINGER, Florentia, BUZDAR, Aman U, SINGLETARY, S. Eva, HORTOBAGYI, Gabriel N, PUSZTAI, Lajos, HATZIS, Christos, RAJAN, Radhika, KUERER, Henry, VALERO, Vicente, ASSAD, Lina, PONIECKA, Anna, HENNESSY, Bryan, GREEN, Marjorie

“…To measure residual disease after neoadjuvant chemotherapy in order to improve the prognostic information that can be obtained from evaluating pathologic…”
Get full text

Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer by Rugo, Hope S, Olopade, Olufunmilayo I, DeMichele, Angela, Yau, Christina, van ’t Veer, Laura J, Buxton, Meredith B, Hogarth, Michael, Hylton, Nola M, Paoloni, Melissa, Perlmutter, Jane, Symmans, W. Fraser, Yee, Douglas, Chien, A. Jo, Wallace, Anne M, Kaplan, Henry G, Boughey, Judy C, Haddad, Tufia C, Albain, Kathy S, Liu, Minetta C, Isaacs, Claudine, Khan, Qamar J, Lang, Julie E, Viscusi, Rebecca K, Pusztai, Lajos, Moulder, Stacy L, Chui, Stephen Y, Kemmer, Kathleen A, Elias, Anthony D, Edmiston, Kirsten K, Euhus, David M, Haley, Barbara B, Nanda, Rita, Northfelt, Donald W, Tripathy, Debasish, Wood, William C, Ewing, Cheryl, Schwab, Richard, Lyandres, Julia, Davis, Sarah E, Hirst, Gillian L, Sanil, Ashish, Berry, Donald A, Esserman, Laura J

“…Using an adaptive trial design to minimize the exposure of patients to inactive agents and to detect more active regimens sooner, investigators found that…”
Get full text

Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor–Positive and –Negative Cancers by Bianchini, Giampaolo, Qi, Yuan, Alvarez, Ricardo H, Iwamoto, Takayuki, Coutant, Charles, Ibrahim, Nuhad K, Valero, Vicente, Cristofanilli, Massimo, Green, Marjorie C, Radvanyi, Laszlo, Hatzis, Christos, Hortobagyi, Gabriel N, Andre, Fabrice, Gianni, Luca, Symmans, W Fraser, Pusztai, Lajos

“…The purpose of this study was to identify genes enriched in breast cancer stroma, assess the stromal gene expression differences between estrogen receptor (ER)…”
Get full text

Survivorship after neoadjuvant chemotherapy – Authors' reply by Yau, Christina, Osdoit, Marie, Esserman, Laura J, Symmans, W Fraser

Get full text

Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry by IWAMOTO, Takayuki, BOOSER, Daniel, MATSUOKA, Junji, YANG, Elliana J, HORTOBAGYI, Gabriel N, HATZIS, Christos, FRASER SYMMANS, W, PUSZTAI, Lajos, VALERO, Vicente, MURRAY, James L, KOENIG, Kimberly, ESTEVA, Francisco J, UENO, Naoto T, JIE ZHANG, WEIWEI SHI, YUAN QI

“…We examined borderline estrogen receptor (ER) -positive cancers, defined as having 1% to 10% positivity by immunohistochemistry (IHC), to determine whether…”
Get full text

The HER‐2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER‐2 Therapy and Personalized Medicine by Ross, Jeffrey S., Slodkowska, Elzbieta A., Symmans, W. Fraser, Pusztai, Lajos, Ravdin, Peter M., Hortobagyi, Gabriel N.

“…Learning Objectives Contrast the current strengths and limitations of the three main slide‐based techniques (IHC, FISH, and CISH) currently in clinical use for…”
Get full text

Adaptive Randomization of Neratinib in Early Breast Cancer by Park, John W, Liu, Minetta C, Yee, Douglas, Yau, Christina, van ’t Veer, Laura J, Symmans, W. Fraser, Paoloni, Melissa, Perlmutter, Jane, Hylton, Nola M, Hogarth, Michael, DeMichele, Angela, Buxton, Meredith B, Chien, A. Jo, Wallace, Anne M, Boughey, Judy C, Haddad, Tufia C, Chui, Stephen Y, Kemmer, Kathleen A, Kaplan, Henry G, Isaacs, Claudine, Nanda, Rita, Tripathy, Debasish, Albain, Kathy S, Edmiston, Kirsten K, Elias, Anthony D, Northfelt, Donald W, Pusztai, Lajos, Moulder, Stacy L, Lang, Julie E, Viscusi, Rebecca K, Euhus, David M, Haley, Barbara B, Khan, Qamar J, Wood, William C, Melisko, Michelle, Schwab, Richard, Helsten, Teresa, Lyandres, Julia, Davis, Sarah E, Hirst, Gillian L, Sanil, Ashish, Esserman, Laura J, Berry, Donald A

“…Among patients with HER2-positive, hormone-receptor–negative locally advanced breast cancer, the addition of neratinib to standard therapy resulted in higher…”
Get full text

Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group by Provenzano, Elena, Bossuyt, Veerle, Viale, Giuseppe, Cameron, David, Badve, Sunil, Denkert, Carsten, MacGrogan, Gaëtan, Penault-Llorca, Frédérique, Boughey, Judy, Curigliano, Giuseppe, Dixon, J Michael, Esserman, Laura, Fastner, Gerd, Kuehn, Thorsten, Peintinger, Florentia, von Minckwitz, Gunter, White, Julia, Yang, Wei, Symmans, W Fraser

“…Neoadjuvant systemic therapy is being used increasingly in the treatment of early-stage breast cancer. Response, in the form of pathological complete response,…”
Get full text

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer by LIEDTKE, Cornelia, MAZOUNI, Chafika, CRISTOFANILLI, Massimo, HORTOBAGYI, Gabriel N, PUSZTAI, Lajos, HESS, Kenneth R, ANDRE, Fabrice, TORDAI, Attila, MEJIA, Jaime A, SYMMANS, W. Fraser, GONZALEZ-ANGULO, Ana M, HENNESSY, Bryan, GREEN, Marjorie

“…Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2…”
Get full text

Effects of Obesity on Transcriptomic Changes and Cancer Hallmarks in Estrogen Receptor-Positive Breast Cancer by FUENTES-MATTEI, Enrique, VELAZQUEZ-TORRES, Guermarie, GULLY, Chris, CARLOCK, Colin, YUAN QI, YA ZHANG, YUN WU, ESTEVA, Francisco J, YONGDE LUO, MCKEEHAN, Wallace L, ENSOR, Joe, HORTOBAGYI, Gabriel N, PHAN, Liem, PUSZTAI, Lajos, SYMMANS, W. Fraser, LEE, Mong-Hong, JIM YEUNG, Sai-Ching, FANMAO ZHANG, CHOU, Ping-Chieh, SHIN, Ji-Hyun, HYUN HO CHOI, CHEN, Jiun-Sheng, RUIYING ZHAO, JIAN CHEN

“…Obesity increases the risk of cancer death among postmenopausal women with estrogen receptor-positive (ER+) breast cancer, but the direct evidence for the…”
Get full text

Simple combination of multiple somatic variant callers to increase accuracy by Trevarton, Alexander J., Chang, Jeffrey T., Symmans, W. Fraser

“…Publications comparing variant caller algorithms present discordant results with contradictory rankings. Caller performances are inconsistent and wide ranging,…”
Get full text

The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues by Marczyk, Michal, Fu, Chunxiao, Lau, Rosanna, Du, Lili, Trevarton, Alexander J, Sinn, Bruno V, Gould, Rebekah E, Pusztai, Lajos, Hatzis, Christos, Symmans, W Fraser

“…Utilization of RNA sequencing methods to measure gene expression from archival formalin-fixed paraffin-embedded (FFPE) tumor samples in translational research…”
Get full text